(Q45163701)

10 December 2017

Risperidone plasma levels, clinical response and side-effects (English)

1 reference

10 December 2017

1 reference

9

H J Möller

1 reference

10 December 2017

Michael Riedel

1

1 reference

10 December 2017

M J Schwarz

2

1 reference

10 December 2017

M Strassnig

3

1 reference

10 December 2017

I Spellmann

4

1 reference

10 December 2017

A Müller-Arends

5

1 reference

10 December 2017

K Weber

6

1 reference

10 December 2017

J Zach

7

1 reference

10 December 2017

N Müller

8

1 reference

10 December 2017

29 November 2004

1 reference

European Archives of Psychiatry and Clinical Neuroscience

10 December 2017

1 reference

10 December 2017

255

1 reference

10 December 2017

261-268

1 reference

10 December 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s00406-004-0556-4

10 December 2017

0 references

cites work

Patient response and resource management: another view of clozapine treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00406-004-0556-4

Determinants of medication compliance in schizophrenia: empirical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-004-0556-4

Psychopharmacologic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-004-0556-4

Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-004-0556-4

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-004-0556-4

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-004-0556-4

Treatment of the neuroleptic-nonresponsive schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-004-0556-4

Atypical neuroleptics: a new approach in the treatment of negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-004-0556-4

Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing

21 January 2018

1 reference

12 December 2020

Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats

1 reference

12 December 2020

Iatrogenic disorders associated with conventional vs. atypical antipsychotics

1 reference

12 December 2020

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

12 December 2020

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

1 reference

12 December 2020

Management of the negative symptoms of schizophrenia: new treatment options

1 reference

12 December 2020

Risperidone and cytochrome P450 3A

1 reference

12 December 2020

Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients

1 reference

12 December 2020

The pharmacokinetics of risperidone in humans: a summary

1 reference

12 December 2020

Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

1 reference

12 December 2020

Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting

1 reference

12 December 2020

A rating scale for drug-induced akathisia

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.

1 reference

12 December 2020

Geriatric psychopharmacology: why does age matter?

1 reference

12 December 2020

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

12 December 2020

Interactions between the cytochrome P450 system and the second-generation antipsychotics

1 reference

12 December 2020

In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.

1 reference

12 December 2020

Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy

1 reference

12 December 2020

Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia

1 reference

12 December 2020

Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients

1 reference

12 December 2020

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis

1 reference

12 December 2020

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

1 reference

12 December 2020

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

1 reference

12 December 2020

Tissue concentrations of clozapine and its metabolites in the rat

1 reference

12 December 2020

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

1 reference

12 December 2020

Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?

1 reference

12 December 2020

Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia

1 reference

12 December 2020

Antipsychotic polypharmacy, part 2: tips on use and misuse

1 reference

12 December 2020

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

12 December 2020

A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.

1 reference

12 December 2020

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

1 reference

12 December 2020

Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population

1 reference

12 December 2020

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

12 December 2020

Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics

1 reference

12 December 2020

Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone

1 reference

12 December 2020

10.1007/S00406-004-0556-4

Identifiers

DOI

1 reference

10 December 2017

1 reference